50270-60-5

Upstream product

• 105-39-5 chloroacetic acid ethyl ester 
• 100-63-0 phenylhydrazine 
• 64-17-5 ethanol 
• 6415-68-5 N-nitroso-N-phenylglycine 
• 2216-92-4 N-phenylglycine ethyl ester 
• 62-53-3 aniline 
• 105-36-2 ethyl bromoacetate 
• 50270-61-6 N-ethoxycarbonylmethyl-N-nitrosoaniline 

Downstream Products

• 175654-38-3 (1,2,3,4-tetrahydro-carbazol-9-yl)-acetic acid ethyl ester 
• 21144-93-4 1,2,3,4-Tetrahydro-9-carbazolyl-essigsaeure 
• 34555-54-9 N-ethoxycarbonylmethyl-N-phenyl-hydrazine hydrochloride 
• 69677-17-4 [N'-((R)-3,6-Bis-benzyloxycarbonylamino-hexanoyl)-N-phenyl-hydrazino]-acetic acid 
• 72462-68-1 (N'-phenyl-hydrazino)-acetic acid ethyl ester 
• 221103-40-8 17-(cyclopropylmethyl)-6,7-dehydro-4,5α-epoxy-3-benzyloxy-14-hydroxy-1'-[2-(p-tolylsulfonyl)oxyethyl]-6,7-2',3'-indolomorphinan 
• 221103-38-4 17-(cyclopropylmethyl)-6,7-dehydro-4,5α-epoxy-3-benzyloxy-14-hydroxy-1'-(2-carboethoxyethyl)-6,7-2',3'-indolomorphinan 
• 221103-39-5 17-(cyclopropylmethyl)-6,7-dehydro-4,5α-epoxy-3-benzyloxy-14-hydroxy-1'-(2-hydroxyethyl)-6,7-2',3'-indolomorphinan 
• 69677-16-3 [N'-((R)-3,6-Bis-benzyloxycarbonylamino-hexanoyl)-N-phenyl-hydrazino]-acetic acid ethyl ester 
• 25081-30-5 (N'-phenyl-hydrazino)-acetic acid 
• 4408-70-2 (N-phenyl-hydrazino)-acetic acid 

Relevant academic research and scientific papers

2,3,4,9-TETRAHYDRO-1H-CARBAZOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS

The invention relates to novel tetrahydro-lH-carbazole derivatives and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and methods of treatment comprising administration of said compounds to patients.

Synthesis of N1'-([18F]fluoroethyl)naltrindole ([18F]FEtNTI): A radioligand for positron emission tomographic studies of delta opioid receptors

N1'-([18F]fluoroethyl)naltrindole ([18F]FEtNTI), a novel analog of the delta opioid receptor antagonist naltrindole (NTI), has been prepared for evaluation as a radioligand for use in positron emission tomography. The precursor for r

Synthesis and pharmacological evaluation of 2,3-dialkylindoles, 'in vitro' inhibitors of thrombin-induced platelet aggregation

A series of 2,3-dialkylindoles (1-5) have been prepared and tested as antithrombotic agents. The whole class showed in vitro interesting activity in the inhibition of thrombin-induced aggregation. Among these compounds some ones showed activity comparable to standards also in the inhibition of collagen-induced aggregation. Owing to a very fast metabolic degradation through a beta-oxidative mechanism, a drastic decrease of activity in several tests ex vivo or in vivo was observed.